Biotech news
Asia
An increasing number of biologics and biosimilar products are appearing in the Thai market, but there are challenges concerning IP protection and regulation, say Alan Adcock and Atthachai Homhuan of Tilleke & Gibbins. 8 September 2016
Americas
The US District Court for the Southern District of Florida ruled yesterday that Apotex did not infringe Amgen patents centring on its biologic drug Neulasta. 7 September 2016
Pharma
The Francis Crick Institute, Europe’s biggest biomedical research institute, has opened in London. 5 September 2016
Americas
Pfizer has unveiled plans to acquire US based biopharmaceutical company Medivation for approximately $14 billion. 22 August 2016
Americas
BioLytical Laboratories, a Canadian based biotech company, has filed two patent applications covering a method for detecting the Zika virus. 22 August 2016
Americas
Bayer has launched a partnership with CRISPR Therapeutics. 19 August 2016
Americas
The US District Court for the District of Massachusetts has issued a ruling on a summary judgment motion filed by Celltrion Healthcare and Hospira, invalidating a Janssen patent related to Remicade. 18 August 2016
Americas
The US Supreme Court’s Mayo and Myriad decisions have brought challenges to subject matter eligibility to the forefront in the biomedical industry, but they do not signal the end of biomedical patents. Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report. 18 August 2016
Americas
The US Patent and Trademark Office has rejected the Broad Institute of MIT and Harvard’s request for a time extension before the start of its patent dispute surrounding the CRISPR technology. 16 August 2016
Asia-Pacific
In Australia, laws governing the patentability of inventions directed to gene-based technology, including isolated naturally occurring and artificial gene sequences, are contentious. Unlike the US situation, the law on patentability of inventions involving “principles of nature” in Australia has yet to be considered judicially, but that is about to change, says Grant Shoebridge of Shelston IP. 16 August 2016